Capricor Therapeutics (CAPR) Total Non-Current Liabilities (2012 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Total Non-Current Liabilities of $13.9 million for Q1 2026, up 268.52% year-over-year from $3.8 million in Q1 2025, and down 2.63% quarter-over-quarter from $14.3 million in Q4 2025.
Capricor Therapeutics (CAPR) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Capricor Therapeutics' Total Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $13.9 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 268.52% year-over-year to $13.9 million; the TTM figure through Mar 2026 stood at $13.9 million (up 268.52% YoY), while the FY2025 annual figure was $14.3 million, up 258.68% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $13.9 million, down from $14.3 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $26.0 million in Q1 2022, with the low at $194603.0 in Q2 2025.
- The 5-year median for Total Non-Current Liabilities is $8.1 million (2023), against an average of $10.0 million.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities surged 660.79% in 2022, then slumped 95.6% in 2025.
- Capricor Therapeutics' Total Non-Current Liabilities stood at $14.7 million in 2022, then plunged by 66.97% to $4.9 million in 2023, then retreated by 17.9% to $4.0 million in 2024, then soared by 258.68% to $14.3 million in 2025, then dropped by 2.63% to $13.9 million in 2026.
- Business Quant data shows CAPR's Total Non-Current Liabilities at $13.9 million in Q1 2026, $14.3 million in Q4 2025, and $14.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | 13.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.94 Mn |
| Dec 31, 2025 | 14.32 Mn |
| Sep 30, 2025 | 14.42 Mn |
| Jun 30, 2025 | 194,603.00 |
| Mar 31, 2025 | 3.78 Mn |
| Dec 31, 2024 | 3.99 Mn |
| Sep 30, 2024 | 4.21 Mn |
| Jun 30, 2024 | 4.42 Mn |
| Mar 31, 2024 | 4.63 Mn |
| Dec 31, 2023 | 4.86 Mn |
| Sep 30, 2023 | 6.01 Mn |
| Jun 30, 2023 | 8.13 Mn |
| Mar 31, 2023 | 10.53 Mn |
| Dec 31, 2022 | 14.72 Mn |
| Sep 30, 2022 | 15.31 Mn |
| Jun 30, 2022 | 19.79 Mn |
| Mar 31, 2022 | 25.96 Mn |
| Dec 31, 2021 | 5.83 Mn |
| Sep 30, 2021 | 3.38 Mn |
| Jun 30, 2021 | 3.38 Mn |